Source: FDA, National Drug Code (US) Revision Year: 2020
ISTURISA (osilodrostat) is a cortisol synthesis inhibitor.
The chemical name of osilodrostat is 4-[(5R)-6,7-Dihydro-5Hpyrrolo[1,2c]imidazol-5-yl]-3-fluorobenzonitrile dihydrogen phosphate.
Molecular formula of osilodrostat salt (phosphate) form on anhydrous basis is: (C13H11FN3) (H2PO4). Relative molecular mass of osilodrostat phosphate salt form is 325.24 g/mol.
ISTURISA tablets for oral administration contains 1 mg, 5 mg, or 10 mg of osilodrostat equivalent to 1.4 mg, 7.2 mg, and 14.3 mg of osilodrostat phosphate respectively, and the following inactive ingredients: colloidal silicon dioxide, croscarmellose sodium, mannitol, microcrystalline cellulose, and magnesium stearate. The film coat is composed of hypromellose, titanium dioxide, ferric oxide (yellow), ferric oxide (red) (1 mg and 10 mg only), ferrosoferric oxide (10 mg only), polyethylene glycol 4000, and talc.
Dosage Forms and Strengths |
---|
ISTURISA is available as:
|
How Supplied | ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ISTURISA (osilodrostat) tablets are supplied as follows:
|
Drug | Countries | |
---|---|---|
ISTURISA | Austria, Estonia, Finland, France, Croatia, Ireland, Israel, Italy, Japan, Lithuania, Poland, Romania, United Kingdom, United States |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.